Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and raises the price target from $135 to $141.
PepGen’s Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta’s Candidate, Says Analyst
September 28, 1:59 PM
PepGen Inc (NASDAQ:PEPG) reported data from PGN-EDO51’s SAD study in adult healthy volunteers that suggest best-in-class exon skipping capabilities. SVB notes…
August 8, 2:09 PM
Sarepta Therapeutics Inc (NASDAQ:SRPT) will license a new group of adeno-associated viruses from the institute for undisclosed upfront payment and milestone…
August 3, 2:20 PM
Sarepta Therapeutics Inc (NASDAQ:SRPT) reported above-consensus 2Q FY22 product sales of $211 million and provided more details on the path forward…
August 1, 10:26 AM
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Sarepta Therapeutics will report an earnings per share (EPS) of $-1.18.
August 1, 3:12 AM
U.S. stocks closed higher on Friday, with the Dow Jones jumping more than 300 points. Here is the list of some big stocks moving higher in the previous session.